[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507348":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":44,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of California, Davis","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Quantitative Neuromuscular Function Monitoring","Quantitative electromyographic (EMG) monitoring",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Ana P Arias, BS","CONTACT","916-703-5456","apaarias@ucdavis.edu",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Julio J Arana Pineda, BA","916-734-4074","jjaranapineda@ucdavis.edu",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"UC Davis Medical Center","RECRUITING","Sacramento","California","95817","United States",{"type":32,"coordinates":33},"Point",[34,35],-121.4944,38.58157,{"lat":35,"lon":34},[38,40],{"name":39,"role":16,"phone":17,"phoneExt":7,"email":18},"Ana Arias",{"name":41,"role":16,"phone":42,"phoneExt":7,"email":43},"Neal Fleming, MD, PhD","916 734-5046","nwfleming@ucdavis.edu",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100507348",false,"NCT05886218","Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery","A Before\u002FAfter Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery","Inclusion Criteria:\n\n* age greater than 18 years\n* scheduled for an elective laparoscopic gastric bypass procedure\n\nExclusion Criteria:\n\n* age less than 18 years\n* pregnancy\n* prisoners\n* significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication\n* patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\\>98%)","ALL","18 Years",{"count":55,"type":56},215,"ESTIMATED","OBSERVATIONAL","This is a single site, prospective, non-blinded, non-randomized, before\u002Fafter study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.",[60],"Sugammadex","2025-05-13",{"date":63,"type":64},"2025-05-15","ACTUAL",{"date":66,"type":64},"2023-02-08",{"date":68,"type":56},"2025-07",{"name":5,"class":6},1]